Skip to main content
SpringerLink
Log in

Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Fifty to sixty percent of postmenopausal women with estrogen receptor positive metastatic breast cancer respond objectively to surgical ablation of the pituitary or adrenal glands. Several investigators have recently developed medical alternatives to surgical ablative therapy for these patients. This review describes one of these strategies, the inhibition of estrogen synthesis with the enzyme inhibitor aminoglutethimide (AG). Aminoglutethimide blocks several cytochrome P-450-mediated steroid hydroxylation steps including those required for cholesterol to pregnenolone conversion and for the aromatization of androgens to estrogens. In women with metastatic carcinoma, a regimen including 1,000 mg of AG and 40 mg of hydrocortisone as replacement glucocorticoid was administered daily. Clinical studies revealed a 32% objective response rate to AG-HC in unselected patients, and a 52% response in women with estrogen receptor positive tumors. Randomized trials revealed that AG-HC produced objective regression as frequently as surgical adrenalectomy (Ag-HC + 53% vs. surgical adrenalectomy (43%,p = NS), and as surgical hypophysectomy (AG-HC 47% vs. hypox 21%,p + NS). Comparison of AG-HC administration with antiestrogen treatment suggested an equal rate of response to either therapy. Preliminary data document responses to AG in antiestrogen-resistant patients. Current studies do not allow precise recommendations regarding the sequence of use of antiestrogens and AG-HC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McGuire WL: Endocrine therapy of breast cancer. Annual Rev Med 26: 353–363, 1975 Clinical Sciences A. Rev Med 26: 353–363, 1975.

    Google Scholar 

  2. McGuire WL, Horwitz KB, Pearson OH, Segaloff A: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39: 2934–2947, 1977

    PubMed  Google Scholar 

  3. McGuire WL, Pearson OH, Segaloff A: Predicting hormone responsiveness in human breast cancer.In McGuire, Carbone, Volmer (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975, pp. 17–30

    Google Scholar 

  4. Robin PE, Dalton GA: The role of major endocrine ablation.In BA Stoll (ed): Breast Cancer Management — Early and Late Year Book, 1977, pp 147–156

  5. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978

    PubMed  Google Scholar 

  6. Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ: Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45: 1322–1325, 1980

    PubMed  Google Scholar 

  7. Santen R, Wells Jr, SA: The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 46: 1066–1074, 1980

    PubMed  Google Scholar 

  8. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB: Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31–37, 1973

    PubMed  Google Scholar 

  9. Santen RJ, Samojlik E: Medical adrenalectomy for treatment of metastatic breast carcinoma.In W McGuire (ed): Breast Cancer, vol. 3. Plenum Publishing, New York, 1979, pp 79–114

    Google Scholar 

  10. Hughes SWM, Burley DM: Aminoglutethimide. A ‘sideeffect’ turned to therapeutic advantage. Postgrad Med J 46: 409–416, 1970

    PubMed  Google Scholar 

  11. Graves PE, Salhanick HA: Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology 105: 52–57, 1979

    PubMed  Google Scholar 

  12. Uzgiris VI, Whipple CA, Salhanick HA: Stereoselective inhibition of cholesterol side chain cleavage by enantiomers of aminoglutethimide. Endocrinology 101: 89–92, 1977

    PubMed  Google Scholar 

  13. Cohen MP, Foa PP: Aminoglutethimide inhibition of adrenal desmolase activity. Proc Soc Exper Biol Med 127: 1086–1090, 1969

    Google Scholar 

  14. Dexter RN, Fishman LM, Ney RL, Liddle GW: Inhibition of adrenal corticosteroid synthesis by aminoglutethimide. Studies of the mechanism of action. J Clin Endocrinol Metab 27: 473–480, 1967

    PubMed  Google Scholar 

  15. Gower DB: Modifiers of steroid-hormone metabolism. A review of their chemistry, biochemistry and clinical application. J Steroid Biochem 5: 501–523, 1974

    PubMed  Google Scholar 

  16. Touitou Y, Bogdan A, Legrand JC, Desgrez P: Aminoglutethimide and glutethimide: Effects on 18-hydroxycorticosterone biosynthesis by human and sheep adrenals in vitro. Acta Endocrinologica, Copenhagen 80: 517–525, 1975

    Google Scholar 

  17. Kowal J: Adrenal cells in tissue culture. IV. Use of an inhibitor of steroid synthesis for the study of ACTH action. Endocrinology 85: 270–279, 1969

    PubMed  Google Scholar 

  18. Schteingart DE, Conn JW: Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab 27: 1657–1666, 1967

    PubMed  Google Scholar 

  19. Chakborty J, Hopkins R, Parke DV: Inhibition studies on the aromatization of androstenedione by human placental microsomal preparations. Biochem J 130: 19, 1972

    PubMed  Google Scholar 

  20. Thompson Jr, EA, Siiteri PK: Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 249: 5364–5372, 1974

    PubMed  Google Scholar 

  21. Thompson Jr, EA, Siiteri PK: The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 249: 5373–5378, 1974

    PubMed  Google Scholar 

  22. Uzgiris VI, Graves P, Salhanick HA: Liquid modification of corpus luteum mitochondrial cytochrome P-450 spectra and cholesterol monooxygenation: An assay of enzyme-specific inhibitors. Biochemistry 16: 593–600, 1977

    PubMed  Google Scholar 

  23. Kahnt, FW, Neher R: Uber die adrenale Steroid-biosynthese in vitro. III. Selektive Hemmung der Nebennierenrinden-funktion. Helv Chim Acta 49: 725–732, 1966

    Google Scholar 

  24. Fishman LM, Liddle GW, Island DP, Fleischer N, Kuchel O: Effects of aminoglutethimide on adrenal function in man. J Clin Endocrinol Metab 27: 481–490, 1967

    PubMed  Google Scholar 

  25. Lipton A, Santen RJ: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33: 503–512, 1974

    PubMed  Google Scholar 

  26. Santen RJ, Lipton A, Kendall J: Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. J Amer Med Assoc 230: 1661–1665, 1974

    Google Scholar 

  27. Santen RJ, Wells SA, Runic S, Gupta C, Kendall J, Ruby EB, Samojlik E: Adrenal suppression with aminoglutethimide. I. Differential effects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone. J Clin Endocrinol Metab 45: 469–479, 1977

    PubMed  Google Scholar 

  28. Buster JE, Abraham GE: Radioimmunoassay of plasma dehydroepiandrosterone sulfate. Analyt Lett 5: 543–551, 1972

    Google Scholar 

  29. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36: 207–214, 1973

    PubMed  Google Scholar 

  30. Thijssen JHH, Poortman J, Schwarz F, Ward F de: Postmenopausal estrogen production with special reference to patients with mammary carcinoma. Front Horm Res 3: 45–62, 1975

    PubMed  Google Scholar 

  31. Adams JB, Li K: Biosynthesis of 17β-oestradiol in human breast carcinoma tissue and a novel method for its characterization. Br J Cancer 31: 429–433, 1975

    PubMed  Google Scholar 

  32. Schweinkert HU, Milewich L, Wilson JD: Aromatization of androstenedione by isolated human hairs. J Clin Endocrinol Metab 40: 413–417, 1975

    PubMed  Google Scholar 

  33. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257–1265, 1978

    PubMed  Google Scholar 

  34. Samojlik E, Veldhuis JD, Wells SA, Santen RJ: Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest 65: 602–612, 1980

    PubMed  Google Scholar 

  35. Samojlik E, Santen RJ: Adrenal suppression with aminoglutethimide. III. Comparison of plasma Δ4 and Δ5-steroids in postmenopausal women treated for breast carcinoma}. J Clin Endocrinol Metab 47: 717–724, 1978

    PubMed  Google Scholar 

  36. Sheppard H, Beaseley JN, Wacker JL: The influence of NADPH or its generating system on corticosteroid biosynthesis by rat adrenal homogenates. Fed Proc 25: 551, 1966 (abstract)

    Google Scholar 

  37. Samojlik E, Santen RJ, Wells SA: Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J Clin Endocrinol Metab 45: 480–487, 1977

    PubMed  Google Scholar 

  38. Newsome Jr, HH, Brown PW, Terz JJ, Lawrence Jr, W: Medical adrenalectomy and plasma steroids in advanced breast carcinoma. Surgery, St. Louis 83: 83–89, 1978

    Google Scholar 

  39. Cash R, Petrini MA, Brough AJ: Ovarian dysfunction associated with an anticonvulsant drug. J Amer Med Assoc 208: 1149–1152, 1969

    Google Scholar 

  40. Kuchel O, Horky K, Gregorova I: The treatment of secondary hyperaldosteronism with oedema by aminoglutethimide. Pharmacol Clin 2: 138–142, 1970

    Google Scholar 

  41. Philbert M, Laudaut MH, Bricaire LH: Etude clinique et biologique d'un inhibiteur de l'hormonosynthese corticosurrenale: l'aminoglutethimide. Ann Endocrinol 29: 189–209, 1966

    Google Scholar 

  42. Santen RJ, Samojlik E, Wells SA: Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 51: 473–477, 1980

    PubMed  Google Scholar 

  43. Glasser SR, Northcutt RC, Chytl F, Strott CA: The influence of an antisteroidogenic drug (aminoglutethimide phosphate) on pregnancy maintenance. Endocrinology 90: 1363–1370, 1972

    PubMed  Google Scholar 

  44. Inaba T, Wiest WG: Inhibitory effects of aminoglutethimide and isoxazole on progesterone production and deciduomal formation in rats. Endocrinology 107: 578–583, 1980

    PubMed  Google Scholar 

  45. Harris A: Therapeutic response and endocrine studies in aminoglutethimide-treated premenopausal women. Presented at a Workshop on Aminoglutethimide by CIBAGEIGY, Basel, 1980

  46. Santen RJ, Wells SA, Cohn N, Demers LM, Misbin RI, Foltz EL: Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. J Clin Endocrinol Metab 45: 739–746, 1977

    PubMed  Google Scholar 

  47. Murray FT, Santner S, Samojlik EA, Santen RJ: Serum aminoglutethimide levels: Studies of serum half-life, clearance and patient compliance. J Clin Pharmacol 19: 704–711, 1979

    PubMed  Google Scholar 

  48. Kennedy BJ: Hormonal therapies in breast cancer.In Varbo, Mastrangelo, Bornstein (eds): Seminars in Oncology, vol. 2, pp 119–130, 1974

  49. Cash R, Brough AJ, Cohen MNP, Satoh PS: Aminoglutethimide (Elipten-CIBA) as an inhibitor of adrenal steroidogenesis. Mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27: 1239–1248, 1967

    PubMed  Google Scholar 

  50. Lawrence BV, Lipton A, Harvey HA, Santen RJ, Wells SA, Cox CE, White DS, Smart EK: Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer 45: 786–791, 1980

    PubMed  Google Scholar 

  51. Santen RJ, Worgul TJ, Harvey H, Lipton A, Boucher A, Smart E, White D, Wells S: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma: Correlation of clinical and hormonal respones. Ann Int Med, 1982 (in press)

  52. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A: A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43: 2207–2214, 1979

    PubMed  Google Scholar 

  53. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: Randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast carcinoma. N Engl J Med 305: 545–551, 1981

    PubMed  Google Scholar 

  54. Newsome HH, Brown PW, Terz JJ, Lawrence Jr, W: Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 39: 542–546, 1977

    PubMed  Google Scholar 

  55. Lipton A, Harvey HA, Santen RJ, Worgul T, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A: Randomized trial of aminoglutethimide vs. tamoxifen in metastatic breast cancer. Abstracts of the Meeting of the American Society for Clinical Oncology, 1981

  56. Smith IE: Comparison of aminoglutethimide with tamoxifen in postmenopausal patients. Presented at a Workshop on Aminoglutethimide by CIBA-GEIGY, Basel, 1980

  57. Murray RML: Results obtained with aminoglutethimide in tamoxifen-resistant patients. Presented at a Workshop on Aminoglutethimide by CIBA-GEIGY, Basel, 1980

  58. Murray RML, Pitt P: Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. Breast Cancer Res Tr 1: 91–95, 1981

    Google Scholar 

  59. Murray RML, Pitt P, Jerums G: Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. Med J Aust 1: 179–181, 1981

    PubMed  Google Scholar 

  60. Paridaens R, Heuson JC: Medical adrenalectomy with aminoglutethimide-cortisol in advanced breast cancer: Clinical results and factors influencing response. Abstracts of the Sixth Congress of European Society for Medical Oncology, Nice, 1980

  61. Paridaens R, Heuson JC: Medical adrenalectomy in advanced breast cancer. Analysis of factors influencing response, oestrogen receptors, tolerance. Presented at a Workshop on Aminoglutethimide by CIBA-GEIGY, Basel, 1980

  62. Harris A: Aminoglutethimide in postmenopausal women. Response rate of patients treated at both branches of the Royal Marsden Hospital. Presented at a Workshop on Aminoglutethimide by CIBA-GEIGY, Basel, 1980

  63. Koelmeyer TD, Stephens EJW, Wood HF: Experience with 6-aminoglutethimide in the treatment of metastatic breast cancer. Clin Oncology 4: 323–327, 1978

    Google Scholar 

  64. Smith IE, Fitzharris BM, McKinna JA, Fahmy DR, Nash AG, Neville AM, Gazet JC, Ford HT, Powels T: Aminoglutethimide in treatment of metastatic breast carcinoma Lancet ii: 646–649, 1978

    Google Scholar 

  65. Wells SA, Santen RJ, Lipton A, Haagensen DE, Ruby EB, Harvey H, Dilley WG: Medical adrenalectomy with aminoglutethimide. Clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 187: 475–484, 1978

    PubMed  Google Scholar 

  66. Worgul TJ, Kendall J, Santen RJ: Recovery of hypothalamic-pituitary-adrenal function after long-term suppression by aminoglutethimide and hydrocortisone. J Clin Endocrinol Metab, 1981 (in press)

  67. Rosenfield RS, Rosenberg BJ, Fukushima DK, Hellman L: 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J Clin Endocrinol Metab 40: 850–855, 1975

    PubMed  Google Scholar 

  68. Samojlik E, Santen RJ: Plasma estrone sulfate: Validity of use for assessing states of reduced estrogen production. Abstracts of the 62nd Annual Meeting of The Endocrine Society, No. 807, 1980

  69. Gale KE, Sheehe PR, Gould LV, Rohner R: Treatment of advanced breast cancer with aminoglutethimide. Clin Res 24: 3976, 1976 (abstract)

    Google Scholar 

  70. Misbin RJ: Aminoglutethimide for metastatic breast cancer. Ann Int Med 86: 828–829, 1977

    PubMed  Google Scholar 

  71. Powles TJ: Aminoglutethimide: Effect on survival in patients with breast cancer. Comparison with chemotherapy. Presented at a Workshop on Aminoglutethimide by CIBA-GEIGY, Basel, 1980

  72. Holdaway IM, Skinner S, Couch RAF, Harvey FJ, Stephens EJ: Prediction of response of human breast cancer to therapy. 6th Int Congr on Endocrinology, Melbourne, 1980 (abstract 814)

  73. Kaye SB: Response of tamoxifen-resistant mammary carcinoma patients to aminoglutethimide. Presented at a Workshop on Aminoglutethimide by CIBA-GEIGY, Basel, 1980

  74. Mason RC, Chetty U, Miller WR, Hawkins RA, Forrest APM: Aminoglutethimide and advanced breast cancer. Trans Biochem Soc 8: 301, 1980

    Google Scholar 

  75. Poli G: Surrenalectomie médicale par aminoglutethimide dans les adenocarcinomes mammaires metastases; these Paris, 1980

  76. Troner MB, Savaraj N: Medical adrenalectomy with aminoglutethimide (AG) in metastatic breast cancer. Proc Am Ass Cancer Res 19: 409, 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, The Milton S. Hershey Medical Center, The Pennsylvania State University, 17033, Hershey, PA, USA

    R. J. Santen M.D.

Authors
  1. R. J. Santen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for reprints: Richard J. Santen, M.D., Division of Endocrinology. The Milton S. Hershey Medical Center, Hershey, PA 17033.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santen, R.J. Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review. Breast Cancer Res Tr 1, 183–202 (1981). https://doi.org/10.1007/BF01806259

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806259

Keywords

Search

Navigation